Dendreon files Provenge BLA
Earlier this week, Dendreon completed its revised BLA for Provenge, taking another big step along the road to marketing a new prostate cancer therapy. Dendreon beat its own timetable and hopes to launch the therapeutic cancer vaccine in 2010. Dendreon release | Story
Comments
Post new comment
Paid Research Reports
- Commercial Insight: Top 20 Cancer Therapy Brands
- Strategies for Managing Pharmaceutical Workforce and Site Reductions: Analysis of legal, productivity, and quality control issue
- The Top 10 Biotechnology Companies: Positioning, performance and SWOT analyses
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
More Research Reports >>
SHARE
WITH: